Literature DB >> 17448024

Prognostic significance of Id-1 and its association with EGFR in renal cell cancer.

X Li1, Z Zhang, D Xin, C W Chua, Y C Wong, S C L Leung, Y Na, X Wang.   

Abstract

AIMS: Epidermal growth factor receptor (EGFR) is suggested as one of the positive regulators in the invasive progression of renal cell cancer (RCC). Recently, Id-1 (inhibitor of differentiation or DNA binding), a helix-loop-helix transcription factor, has been identified as one of the key factors in the EGFR signalling pathway. The aim of this study was to investigate the significance of Id-1 expression in renal cell cancer and to study its relationship with EGFR. METHODS AND
RESULTS: Id-1 and EGFR expression was examined in tissue microarray (TMA) samples of 107 RCC and 32 normal kidney specimens by immunohistochemistry. Relative Id-1 and EGFR protein expression was quantified by estimating the staining intensity on a four-grade scale. We found that while negative to weak expression of Id-1 and EGFR was observed in non-malignant kidney tissues, most RCCs showed significant positive Id-1 and EGFR expression in tumour cells. In addition, Id-1 immunostaining intensity was positively associated with increased tumour staging, grading and EGFR expression.
CONCLUSION: Overexpression of Id-1 is a novel marker for advanced RCC which is positively correlated with EGFR expression. Our results suggest that Id-1 may play an important role in the development of RCC and indicate that Id-1 is a potential marker of patients with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448024     DOI: 10.1111/j.1365-2559.2007.02637.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  12 in total

1.  Assessing the application of tissue microarray technology to kidney research.

Authors:  Ming-Zhi Zhang; Yinghao Su; Bing Yao; Wei Zheng; Mark Decaestecker; Raymond C Harris
Journal:  J Histochem Cytochem       Date:  2010-01-19       Impact factor: 2.479

Review 2.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

3.  ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.

Authors:  Smitha Pillai; Wasia Rizwani; Xueli Li; Bhupendra Rawal; Sajitha Nair; Michael J Schell; Gerold Bepler; Eric Haura; Domenico Coppola; Srikumar Chellappan
Journal:  Mol Cell Biol       Date:  2011-05-23       Impact factor: 4.272

4.  Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.

Authors:  Krishnendu Pal; Ying Cao; Irina N Gaisina; Santanu Bhattacharya; Shamit K Dutta; Enfeng Wang; Hendra Gunosewoyo; Alan P Kozikowski; Daniel D Billadeau; Debabrata Mukhopadhyay
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

Review 5.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

Review 6.  ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Authors:  Radhika Nair; Wee Siang Teo; Vivek Mittal; Alexander Swarbrick
Journal:  Mol Ther       Date:  2014-05-14       Impact factor: 11.454

7.  Probasin promoter-driven expression of ID1 is not sufficient for carcinogenesis in rodent prostate.

Authors:  Robert Salomon; Lei Young; Duncan Macleod; Xiao-Ling Yu; Qihan Dong
Journal:  J Histochem Cytochem       Date:  2009-03-02       Impact factor: 2.479

8.  Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.

Authors:  Erik Hedrick; Syng-Ook Lee; Gyungeun Kim; Maen Abdelrahim; Un-Ho Jin; Stephen Safe; Ala Abudayyeh
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

9.  Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy.

Authors:  Ibrahim Meteoglu; Nezih Meydan; Muhan Erkus
Journal:  J Exp Clin Cancer Res       Date:  2008-11-12

10.  ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.

Authors:  Xin Yin; Bei Tang; Jing-Huan Li; Yan Wang; Lan Zhang; Xiao-Ying Xie; Bo-Heng Zhang; Shuang-Jian Qiu; Wei-Zhong Wu; Zheng-Gang Ren
Journal:  J Exp Clin Cancer Res       Date:  2017-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.